37
Participants
Start Date
July 31, 2000
Primary Completion Date
June 26, 2007
Study Completion Date
July 26, 2010
alemtuzumab
Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
Northwestern University, Northwestern Medical Faculty Foundation, Chicago
Veterans Affairs Medical Center - Lakeside Chicago, Chicago
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Genzyme, a Sanofi Company
INDUSTRY
Northwestern University
OTHER